Literature DB >> 22555562

[Esophagitis during immunosuppression].

F Moosig1, W L Gross.   

Abstract

Esophagitis due to cytomegalovirus (CMV) has mostly been described in patients with acquired immunodeficiency syndrome (AIDS). Distal and hemorrhagic ulcerations are characteristic. A CMA esophagitis can, however, also occur in patients with no human immunodeficiency virus (HIV) infection as a complication of immunosuppressive therapy. In the case example presented here the disease was due to an excessive dosage of prednisolone medication over a period of many years. In all published cases of CMV esophagitis with rheumatic diseases, there was also a high dosage of glucocorticoid medication. To avoid complications regular rheumatological screening controls and adjustment of immunosuppressive therapy are therefore important to maintain control of the disease with low dosage glucocorticoids.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22555562     DOI: 10.1007/s00393-012-0963-2

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  4 in total

1.  Cytomegalovirus esophagitis as a treatable complication of systemic sclerosis.

Authors:  M A Contreras; C Salas; J L Andreu; J Mulero
Journal:  J Clin Rheumatol       Date:  2001-12       Impact factor: 3.517

2.  Interrelationships among quantity of human cytomegalovirus (HCMV) DNA in blood, donor-recipient serostatus, and administration of methylprednisolone as risk factors for HCMV disease following liver transplantation.

Authors:  A V Cope; C Sabin; A Burroughs; K Rolles; P D Griffiths; V C Emery
Journal:  J Infect Dis       Date:  1997-12       Impact factor: 5.226

3.  Prospective endoscopic characterization of cytomegalovirus esophagitis in AIDS.

Authors:  C M Wilcox; R F Straub; D A Schwartz
Journal:  Gastrointest Endosc       Date:  1994 Jul-Aug       Impact factor: 9.427

Review 4.  Value of anti-infective chemoprophylaxis in primary systemic vasculitis: what is the evidence?

Authors:  Frank Moosig; Julia U Holle; Wolfgang L Gross
Journal:  Arthritis Res Ther       Date:  2009-10-28       Impact factor: 5.156

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.